PIN137 HIV Regulatory Practices and Their Influence Over Reimbursement Decisions  by Rubinstein, J. et al.
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A365
for the FDA, EMA, Health Canada and Australia the Australian Therapeutic Goods 
Administration. The studies used to make regulatory decisions were then compared 
to the studies used in the reimbursement decisions of France, Scotland, Canada and 
Australia. Results: In all 15 cases reviewed the FDA, EMA and Health Canada used 
at least one of the same studies to come to their decision and in 13 of the cases 
Australia also used that same study. In 14 cases the FDA approved the drug before 
the other regulatory authorities; the longest time before another regulatory agency 
approved a drug was 15 months for rilpivirine. In six cases the FDA commissioned 
studies that other regulatory bodies and reimbursement agencies used later. All 
of the studies were interventional studies. Reimbursement agencies always used 
studies that were previously cited in regulatory documents. These agencies would 
also use studies intended for the regulatory approval of another drug as a source 
for information in a review. ConClusions: Reimbursement agencies and other 
regulatory agencies are influenced by the FDA in the studies they consider, as illus-
trated by at least six cases in which other agencies used studies commissioned by 
the FDA after approval. This influence is easier to see in the last five years, but may 
be older than that due to improvements in published reports.
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objeCtives: General practitioners (GPs) play an essential role in France in the 
prescription and administration of vaccines. Understanding factors that influence 
GPs’ opinions regarding vaccination would help improve vaccination rate in the 
general population. The study objectives were to understand and describe GPs’ 
attitudes, beliefs and behaviours regarding vaccination, to develop a self-report 
tool enabling characterisation of GPs, to assess the prevalence and determinants of 
vaccination behaviours and to identify the modifiable barriers regarding vaccina-
tion. Methods: Focus groups with French GPs (n= 36) were conducted following a 
semi-structured interview guide. Main themes of the guide were identified through 
a literature review. Qualitative analysis enabled development of a conceptual frame-
work based on the theory of planned behaviour (TPB). Items were then generated 
based on GPs’ quotations. Cognitive debriefing interviews with GPs (n= 10) were 
conducted to assess understanding, acceptability and content validity of the tool. 
Research methods and results were approved by a committee involving GPs, vac-
cination and tool development experts. Results: Focus groups revealed that GPs’ 
attitudes, beliefs and behaviours regarding vaccination varied depending on target 
disease and population. GPs were influenced by factors classified in 6 themes: vac-
cine characteristics, disease characteristics, practical aspects, expected benefits, 
personal background and relationship with patients. These qualitative findings 
supported item generation of the tool to capture 39 detailed concepts. The tool was 
developed to be generic for any disease that could be prevented by vaccination. 
Comprehension testing to confirm the relevance and understanding of the tool is 
underway. ConClusions: The tool was developed following rigorous methodology 
based on documented qualitative research. The TPB seems appropriate for organis-
ing qualitative research findings. Characterisation of GPs based on their attitudes, 
beliefs and behaviours regarding vaccination is expected to predict their intention 
to vaccinate and thus enable development of efficient programs promoting vac-
cination. The next step is to perform psychometric validation.
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objeCtives: It is assumed that agencies influence one another but little has 
been written on the extent of this influence. This analysis aims to explore how 
regulatory decisions affect reimbursement decisions within one HIV drug, daru-
navir. Methods: Documents from the FDA, European Public Assessment Report 
(EPAR), Health Canada, and the Australian Register of Therapeutic Goods together 
with the reimbursement decisions from France, Scotland, Canada and Australia were 
analyzed. The clinical trials found in these documents were compared. Results: 
The FDA approved darunavir ethanolate on June 23, 2006 based on the POWER 1, 2 
and 3 clinical trials. After approval, the FDA also required further reports (to be com-
pleted by December 31, 2007) on two Phase III studies, ARTEMIS and TITAN. Health 
Canada approved darunavir on July 28, 2006 and used the POWER studies along 
with the ARTEMIS and TITAN studies in its decision. The EMA approved darunavir 
on December 2, 2007 but gave conditional authorization a year earlier. EPAR also 
used the TITAN and POWER studies to make its decision. The French reimbursement 
agency used the ARTEMIS and TITAN studies in two recommendations. Scotland 
and Canada cited the ARTEMIS study in their recommendations. Australia used the 
POWER and TITAN studies in two recommendations and the ARTEMIS study in its 
one negative recommendation, citing an inappropriate comparator for the popula-
tion under review. ConClusions: Studies that required further review by the FDA 
after approval were key in determining regulatory decisions by Health Canada, 
EMA and Australia. The reimbursement decisions of France, Scotland, Canada and 
Australia also relied on these commissioned studies.
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chronic (e.g., diabetes, hypercholesterolemia, schizophrenia) rather than life-threat-
ening and that treatments, while costly, lead to significant savings in medical ben-
efits and ultimately leave medication decisions to specialists. Payers are cautiously 
examining potential savings and were willing to institute modest management for 
generics (tier 1) while keeping branded FDCs on preferred tier 2 (branded preferred 
copay). Payers were unwilling to institute, high cost-sharing co-insurance, prior 
authorizations, or require failure for members to access branded HIV medications 
presently or in the near future. ConClusions: Payers recognize the complexity 
of treating HIV, the role of adherence, the high cost of failure and the public health 
component of preventing resistance. We found payers to cautiously look at potential 
cost savings in medication management until all FDC components become generic. 
We found no widespread desire to drive generic adoption in HIV treatment, and little 
interest in the “de-simplification” of currently available FDCs.
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objeCtives: Inadequate or partial treatment of Tuberculosis (TB) is a known factor 
that would promote drug resistance, thus increasing the overall cost of TB manage-
ment. The study objectives are to identify the general characteristics of defaulting 
patients and to estimate the cost impact on health authorities as compared to non-
defaulters. Methods: A retrospective case-control study was carried out in public 
treatment centres in Selangor, Malaysia. Defaulter is defined as TB patient who has 
interrupted treatment for two consecutive months or more and did not complete 
their treatment. All subjects were selected from 2011 TB District Registry database. 
Patients’ medical case notes and baseline characteristics were reviewed and analysed. 
The direct costs of TB management were estimated from public health cost refer-
ences. The study was performed from a government’s perspective. Results: A total 
of 176 defaulters and 204 non-defaulters were studied. Foreign-born patients showed 
a higher risk (OR= 5.929; p < 0.01) of defaulting treatment. Unemployed patients were 
also more likely to default treatment (OR= 1.521 p> 0.05). Defaulters were more likely 
to default treatment during intensive phase as compared to maintenance phase 
(68.1% vs. 31.9%; p< 0.05). No other significant findings were observed between the 
two groups including age, ethnicity, severity of x-ray changes, type of TB and overall 
medical risk factors. Mean cost of the non-defaulter group is higher than the defaulter 
group due to a complete treatment (RM 1,259.62 vs. RM 575.58; p< 0.05). No significant 
treatment cost difference was observed in foreign-born defaulters as compared to 
local Malaysians (mean: RM 576.43 vs. RM 573.78; p> 0.05). ConClusions: Data from 
this study suggest TB treatment should be completed to avoid a potential huge waste 
of resources. More attentions are required for foreign-born defaulters due to over-
all consequence in public health and management cost. Additional costs would be 
required if susceptible TB strains of the defaulters turned into more virulent strains.
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objeCtives: To describe the burden of influenza for children and adults diagnosed 
with seasonal influenza in Germany. Methods: The study was based on a retro-
spective database analysis, using a longitudinal electronic medical records database 
(IMS® Disease Analyzer). Patients with influenza episodes (ICD-10 diagnosis J09-
11) being observable 12 months before index date and 1 month afterwards were 
included. The selection window was May 2010 to April 2012 to cover two influenza 
seasons. Results: A total of 23,068 influenza episodes (19,446 patients) managed 
by primary care practitioners (PCP) and 7,295 episodes (5,988 patients) managed by 
pediatricians were eligible. Mean age of patients was 43±20 years in the PCP panel 
and 7±4 years in the pediatrician panel. The presence of clinical risk factors was 
documented for 40% of episodes in adults and 31% of episodes in children. The most 
common risk factors were cardiovascular diseases in adults (28%) and chronic res-
piratory diseases in children (26%). The presence of risk factors correlated with the 
number of episodes/patient. Influenza episodes were frequently accompanied by 
complications (adults: 38%; children: 57%). Bronchitis (adults: 16%, children: 20%) 
and acute upper respiratory infections (adults: 15%, children: 21%) accounted for the 
most frequent complications. Mean number of physician visits was 1.2± 0.5 in adults 
and 1.5±0.8 in children. Nevertheless one in three children (34%) had more than one 
visit/episode due to complications. About 60% of episodes (adults: 60%; children: 64%) 
with at least one complication were reported in patients without risk factors. About 
50% of patients received drug prescriptions related either to influenza diagnosis or 
complications. ConClusions: This study demonstrates that in Germany seasonal 
influenza is associated with a substantial disease burden and considerable resource 
utilization, which can be preventable by vaccination. The findings may suggest the 
modification of the current vaccination recommendation for at risk populations.
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objeCtives: This analysis compares the studies that four regulatory agencies used 
to make their decisions and compares the relationship between the reasons for 
regulatory decisions and reasons for reimbursement decisions. Methods: The 
scientific discussions and the studies used to make regulatory decisions for 15 
different HIV drugs approved over the last 12 years (2000-2012) were compared 
